Top pick for banking + investing in one app
- Trade stocks, options, ETFs and mutual funds
- Access to a financial planner
- All-in-one app for banking and investing
- Automated investing available

By
Matt MiczulskiReviewed by
Richard LaycockUpdated
Oura has become one of the most recognizable names in the wearables space, known for its ring-shaped health tracker that monitors sleep, recovery and a growing list of biometric signals. As competition in the smart ring category heats up and demand for personal health data grows, you might be wondering if it's possible to buy Oura stock. Oura publicly filed its S-1 registration statement with the SEC on September 3, 2026, setting up a Nasdaq debut under the ticker "OURA." Here's what you need to know about the IPO and Oura's valuation until shares begin trading.
Oura Health publicly filed its S-1 registration statement with the US Securities and Exchange Commission on September 3, 2026, confirming plans to list on the Nasdaq Global Select Market under the ticker "OURA."(1) The filing follows a confidential draft submission made in May 2026 and replaces those earlier private estimates with audited financials. Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen & Company and Jefferies are named as lead underwriters, with more than a dozen additional banks participating, including Robinhood Securities.(1)
The filing doesn't disclose a price range, share count or number of shares being offered — those details, along with the final valuation, will be set closer to pricing.(1)
The financials in the S-1 show a company that's grown quickly and turned a corner into profitability. Oura reported revenue of $1.21 billion for the nine months ended June 30, 2026, up 74% year-over-year, with a 55% gross margin and net income of $60.8 million over that period.(1) That compares with a net income of just $12,000 for the full 2025 fiscal year, showing the profitability is a recent development.(1)
Oura postponed its Nasdaq IPO on September 29, 2026, citing uncertainty in the IPO market, just eight days after formally launching the offering with plans to sell 50 million shares and raise up to $2.2 billion.(2)
The company said demand was strong and its business had strengthened since the IPO process began, and CEO Tom Hale said Oura has the luxury of choosing when to go public.(2)Once Oura goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.
Top pick for banking + investing in one app
Get 12 free shares
Top pick for integrated stock & crypto investing
T&Cs apply
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Oura stock.
See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.Looking for other options? Check out these similar products.
How we picked theseThe Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on eight different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Finder writers are subject matter experts and use primary sources, in-depth research and interviews with other experts to ensure you're getting accurate, up-to-date information. Articles are fact checked in line with our editorial guidelines.
Matt Miczulski is an investments editor and market analyst at Finder. With over 450 bylines, Matt dissects and reviews brokers and investing platforms to expose perks and pain points, explores investment products and concepts and covers market news, making investing more accessible and helping readers to make informed financial decisions. Before joining Finder in 2021, Matt covered everything from finance news and banking to debt and travel for FinanceBuzz. His expertise and analysis on investing and other financial topics has been featured on Yahoo Finance, CBS, MSN, Best Company and Consolidated Credit, among others. Matt holds a BA in history from William Paterson University. See full bio
Everything we know about the Kalshi IPO, plus information on how to buy in.
Everything we know about the Pershing Square Capital Management IPO, plus information on how to buy in.
Everything we know about the Medline IPO, plus information on how to buy in.
Everything we know about the Wealthfront IPO, plus information on how to buy in.
Everything we know about the Gloo IPO, plus information on how to buy in.
Everything we know about the Figure IPO, plus information on how to buy in.
Everything we know about the Klarna IPO, plus information on how to buy in.
Finder is a comparison platform and information service designed to help you make better decisions. To keep our service free, we receive compensation from the companies whose products or services we feature on our site.
We may be paid when you click on a link, submit an application, or open an account.
Our commercial arrangements affect which products we write about, as well as the inclusion, order, position and placement of products on our site. They do not influence our independent assessments or editorial views, which are based on research and expert analysis conducted by our editorial team.
The inclusion of a provider or product in our content, or the order in which products appear in tables or lists, is not an endorsement or recommendation from us.
We compare a wide range of products, providers and services, but we don't cover the whole market. Not every company or offer available is included on our site, and other options may be available to you.
The information we provide is general in nature and is not financial, investment, tax or legal advice. Consider your own circumstances and read the provider's terms and conditions before making a decision.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.